All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

dorzolamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	949	120279-96-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dorzolamide dorzolamide hydrochloride dorzolamide HCl	topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer Molecular weight: 324.43 Formula: C10H16N2O4S3 CLOGP: 0.15 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 106.33 ALOGS: -2.67 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.30	ml	None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	14 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	3.08 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PRKDC,TEK	20
kinase-selectivity-class	AXL,GRK2,MAP2K6,PDK1,TEK,ZAP70	6
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1994	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	341.21	15.92	88	8586	7005	90612768
Eye irritation	281.24	15.92	110	8564	33868	90585905
Treatment failure	256.33	15.92	220	8454	303708	90316065
Ocular hyperaemia	145.64	15.92	69	8605	33729	90586044
Eye pain	145.21	15.92	75	8599	44093	90575680
Glaucoma	126.49	15.92	54	8620	20701	90599072
Visual acuity reduced	110.76	15.92	51	8623	23359	90596414
Choroidal effusion	91.68	15.92	20	8654	769	90619004
Product quality issue	84.52	15.92	66	8608	79259	90540514
Product container issue	71.48	15.92	20	8654	2161	90617612
Product delivery mechanism issue	70.80	15.92	15	8659	501	90619272
Corneal oedema	69.52	15.92	19	8655	1882	90617891
Ocular surface disease	69.26	15.92	11	8663	67	90619706
Product packaging quantity issue	58.53	15.92	16	8658	1586	90618187
No adverse event	56.54	15.92	49	8625	67933	90551840
Burns second degree	55.18	15.92	16	8658	1964	90617809
Catarrh	53.62	15.92	15	8659	1619	90618154
Hypotony of eye	51.30	15.92	10	8664	218	90619555
Choroidal detachment	48.94	15.92	10	8664	279	90619494
Steroid dependence	48.76	15.92	15	8659	2254	90617519
Vision blurred	43.18	15.92	53	8621	110240	90509533
Iridocyclitis	41.71	15.92	15	8659	3646	90616127
Hypopnoea	38.92	15.92	15	8659	4416	90615357
Bradycardia	37.28	15.92	43	8631	83804	90535969
Visual impairment	37.06	15.92	54	8620	132311	90487462
Gingival pain	36.39	15.92	18	8656	9634	90610139
Accidental overdose	35.57	15.92	26	8648	28247	90591526
Product dose omission issue	35.53	15.92	83	8591	291604	90328169
Superficial injury of eye	34.66	15.92	8	8666	398	90619375
Iritis	34.25	15.92	13	8661	3673	90616100
Glaucoma surgery	33.49	15.92	6	8668	81	90619692
Trabeculectomy	31.41	15.92	5	8669	31	90619742
Hyphaema	30.12	15.92	7	8667	359	90619414
Thermal burns of eye	29.34	15.92	6	8668	168	90619605
Punctate keratitis	29.31	15.92	8	8666	788	90618985
Cataract	28.78	15.92	35	8639	72057	90547716
Erythema of eyelid	28.43	15.92	11	8663	3272	90616501
Eye pruritus	28.42	15.92	23	8651	29004	90590769
Foreign body sensation in eyes	28.38	15.92	11	8663	3289	90616484
Ulcerative keratitis	27.89	15.92	11	8663	3442	90616331
Acute generalised exanthematous pustulosis	27.88	15.92	17	8657	13686	90606087
Conjunctival follicles	27.23	15.92	4	8670	13	90619760
Dysgeusia	26.87	15.92	29	8645	52531	90567242
Angle closure glaucoma	26.56	15.92	10	8664	2765	90617008
Impaired quality of life	26.24	15.92	20	8654	23124	90596649
Retinal disorder	26.22	15.92	9	8665	1910	90617863
Parosmia	26.11	15.92	13	8661	7056	90612717
Joint swelling	25.90	15.92	8	8666	503292	90116481
Rhinitis	25.49	15.92	16	8658	13556	90606217
Swollen tongue	24.62	15.92	26	8648	45930	90573843
Conjunctival erosion	23.84	15.92	5	8669	159	90619614
Blindness	23.81	15.92	20	8654	26548	90593225
Conjunctivitis	23.72	15.92	20	8654	26686	90593087
Genital erythema	23.52	15.92	4	8670	39	90619734
Lacrimation increased	23.49	15.92	20	8654	27042	90592731
Eye disorder	23.28	15.92	20	8654	27370	90592403
Hypoglycaemia	23.28	15.92	31	8643	69817	90549956
Visual field defect	23.04	15.92	12	8662	7154	90612619
Tinnitus	22.41	15.92	24	8650	43078	90576695
Conjunctival scar	22.33	15.92	4	8670	54	90619719
Intraocular pressure test abnormal	22.20	15.92	5	8669	223	90619550
Abnormal sensation in eye	22.17	15.92	8	8666	1963	90617810
Maternal exposure during pregnancy	21.90	15.92	4	8670	360059	90259714
Conjunctival hyperaemia	21.82	15.92	9	8665	3160	90616613
Eye discharge	21.44	15.92	12	8662	8246	90611527
Ocular discomfort	21.44	15.92	11	8663	6359	90613414
Palpitations	21.29	15.92	43	8631	136685	90483088
Cardiac murmur	21.24	15.92	16	8658	18178	90601595
Intraocular pressure fluctuation	21.20	15.92	4	8670	73	90619700
Conjunctivitis allergic	21.17	15.92	7	8667	1325	90618448
Nightmare	20.81	15.92	17	8657	21708	90598065
Intraocular lens implant	19.51	15.92	5	8669	386	90619387
Rectal haemorrhage	19.26	15.92	31	8643	82713	90537060
Conjunctival oedema	19.11	15.92	6	8668	963	90618810
Infusion related reaction	19.10	15.92	8	8666	416772	90203001
Eye complication associated with device	19.07	15.92	3	8671	17	90619756
Retinal vascular occlusion	18.92	15.92	5	8669	436	90619337
Glossodynia	18.67	15.92	4	8670	321775	90297998
Uveitis	18.60	15.92	14	8660	15889	90603884
Corneal neovascularisation	18.51	15.92	4	8670	147	90619626
Impaired work ability	18.26	15.92	15	8659	19311	90600462
Device deposit issue	17.96	15.92	3	8671	26	90619747
Product package associated injury	17.57	15.92	3	8671	30	90619743
Wound	17.11	15.92	4	8670	302976	90316797
Arthropathy	16.82	15.92	7	8667	366235	90253538
Urine output decreased	16.78	15.92	12	8662	12591	90607182
Blepharitis	16.75	15.92	8	8666	3968	90615805
Thyroxine decreased	16.74	15.92	5	8669	680	90619093
Iris hyperpigmentation	16.64	15.92	3	8671	42	90619731
Bronchiectasis	16.38	15.92	15	8659	22315	90597458
Acute lymphocytic leukaemia	16.00	15.92	7	8667	2841	90616932
Accidental exposure to product	15.99	15.92	20	8654	42346	90577427

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	265.61	21.43	87	10147	6346	42604755
Burns second degree	241.85	21.43	80	10154	6016	42605085
Catarrh	239.26	21.43	79	10155	5907	42605194
Steroid dependence	234.18	21.43	80	10154	6642	42604459
Parosmia	223.64	21.43	80	10154	7611	42603490
Hypopnoea	221.72	21.43	80	10154	7802	42603299
Gingival pain	215.88	21.43	80	10154	8414	42602687
Systemic lupus erythematosus	208.62	21.43	80	10154	9244	42601857
Rhinitis	192.56	21.43	81	10153	11896	42599205
Treatment failure	188.16	21.43	140	10094	62484	42548617
Impaired work ability	185.17	21.43	79	10155	12012	42599089
Cardiac murmur	184.25	21.43	80	10154	12695	42598406
Bronchiectasis	169.78	21.43	84	10150	17935	42593166
Eye irritation	163.61	21.43	71	10163	11247	42599854
Swollen tongue	156.77	21.43	84	10150	21147	42589954
Frequent bowel movements	153.32	21.43	83	10151	21324	42589777
Alcohol poisoning	151.76	21.43	60	10174	7514	42603587
Impaired quality of life	145.27	21.43	70	10164	14107	42596994
Nightmare	143.90	21.43	84	10150	24928	42586173
Migraine	137.43	21.43	82	10152	25332	42585769
Colitis ulcerative	135.19	21.43	82	10152	26093	42585008
Tinnitus	135.10	21.43	85	10149	28853	42582248
Eczema	131.89	21.43	89	10145	33997	42577104
Dysgeusia	131.65	21.43	89	10145	34100	42577001
Accidental overdose	129.21	21.43	82	10152	28248	42582853
Medication error	126.92	21.43	86	10148	33068	42578033
Vertigo	121.82	21.43	85	10149	34262	42576839
Eye pain	119.06	21.43	65	10169	16965	42594136
Tubulointerstitial nephritis	116.41	21.43	80	10154	31468	42579633
Arthritis	115.08	21.43	89	10145	41976	42569125
Stress	109.03	21.43	88	10146	44124	42566977
Rectal haemorrhage	104.22	21.43	90	10144	49516	42561585
Palpitations	94.44	21.43	86	10148	50711	42560390
Haematochezia	93.45	21.43	91	10143	58345	42552756
Loss of personal independence in daily activities	91.94	21.43	84	10150	49732	42561369
Inappropriate schedule of product administration	79.20	21.43	106	10128	95796	42515305
Visual acuity reduced	73.08	21.43	48	10186	17502	42593599
Adverse drug reaction	72.74	21.43	65	10169	37369	42573732
Deep vein thrombosis	68.06	21.43	88	10146	76869	42534232
Intentional product use issue	68.04	21.43	85	10149	71748	42539353
Abdominal discomfort	68.04	21.43	87	10147	75168	42535933
Cerebrovascular accident	67.71	21.43	99	10135	97061	42514040
Ocular hyperaemia	67.30	21.43	44	10190	15919	42595182
Corneal oedema	64.11	21.43	21	10213	1527	42609574
Depression	54.97	21.43	97	10137	111266	42499835
Ocular surface disease	54.89	21.43	11	10223	104	42610997
Pain in extremity	52.20	21.43	113	10121	150491	42460610
Confusional state	50.57	21.43	119	10115	167478	42443623
Blepharitis	48.32	21.43	18	10216	1915	42609186
Glaucoma	45.55	21.43	27	10207	8221	42602880
COVID-19	44.81	21.43	91	10143	115857	42495244
Product container issue	44.41	21.43	14	10220	900	42610201
Hyphaema	43.34	21.43	13	10221	707	42610394
Pulmonary embolism	41.70	21.43	90	10144	119522	42491579
Anterior chamber disorder	39.70	21.43	8	10226	78	42611023
Weight decreased	38.08	21.43	123	10111	207825	42403276
Product quality issue	36.61	21.43	32	10202	17850	42593251
Product delivery mechanism issue	35.60	21.43	9	10225	257	42610844
Product use in unapproved indication	34.57	21.43	110	10124	184346	42426755
Choroidal detachment	33.59	21.43	10	10224	530	42610571
Eye pruritus	33.04	21.43	25	10209	11387	42599714
Somnolence	32.95	21.43	91	10143	141014	42470087
Headache	32.21	21.43	128	10106	239241	42371860
Lacrimation increased	30.21	21.43	24	10210	11734	42599367
Scleral hyperaemia	28.95	21.43	6	10228	68	42611033
Product packaging quantity issue	28.08	21.43	11	10223	1342	42609759
Vision blurred	28.05	21.43	48	10186	53651	42557450
Ulcerative keratitis	26.61	21.43	12	10222	2076	42609025
Toxicity to various agents	26.41	21.43	11	10223	229125	42381976
Intraocular pressure test abnormal	26.21	21.43	6	10228	111	42610990
Congenital vas deferens absence	25.81	21.43	5	10229	39	42611062
Congenital muscle absence	25.81	21.43	5	10229	39	42611062
Rash	25.21	21.43	132	10102	276822	42334279
Pain	24.60	21.43	120	10114	244728	42366373
Iridocyclitis	22.88	21.43	11	10223	2200	42608901
Cardioactive drug level increased	22.19	21.43	10	10224	1727	42609374
Myopic chorioretinal degeneration	22.00	21.43	3	10231	0	42611101
No adverse event	21.86	21.43	36	10198	38985	42572116

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intraocular pressure increased	453.30	16.82	131	15512	10745	110562911
Burns second degree	326.01	16.82	94	15549	7639	110566017
Catarrh	321.92	16.82	92	15551	7243	110566413
Steroid dependence	313.20	16.82	93	15550	8376	110565280
Hypopnoea	286.14	16.82	93	15550	11287	110562369
Parosmia	272.73	16.82	93	15550	13087	110560569
Gingival pain	264.11	16.82	95	15548	15641	110558015
Rhinitis	230.91	16.82	95	15548	22450	110551206
Cardiac murmur	219.50	16.82	94	15549	24534	110549122
Impaired work ability	200.31	16.82	90	15553	26329	110547327
Eye irritation	194.95	16.82	95	15548	33357	110540299
Bronchiectasis	192.97	16.82	97	15546	36396	110537260
Nightmare	190.08	16.82	98	15545	38765	110534891
Accidental overdose	182.12	16.82	105	15538	51729	110521927
Impaired quality of life	180.20	16.82	87	15556	29930	110543726
Alcohol poisoning	180.17	16.82	62	15581	8958	110564698
Swollen tongue	174.91	16.82	108	15535	60254	110513402
Tinnitus	164.53	16.82	104	15539	60436	110513220
Dysgeusia	157.90	16.82	107	15536	69878	110503778
Eczema	150.06	16.82	105	15538	72188	110501468
Visual acuity reduced	148.35	16.82	78	15565	32095	110541561
Tubulointerstitial nephritis	146.87	16.82	93	15550	54191	110519465
Frequent bowel movements	135.06	16.82	98	15545	71292	110502364
Vertigo	132.83	16.82	105	15538	86765	110486891
Eye pain	130.98	16.82	84	15559	50015	110523641
Rectal haemorrhage	128.24	16.82	118	15525	119715	110453941
Colitis ulcerative	123.65	16.82	96	15547	77267	110496389
Haematochezia	122.15	16.82	113	15530	115411	110458245
Corneal oedema	117.96	16.82	35	15608	3138	110570518
Ocular surface disease	112.93	16.82	20	15623	164	110573492
Medication error	109.33	16.82	102	15541	105264	110468392
Ocular hyperaemia	107.98	16.82	68	15575	39218	110534438
Stress	107.42	16.82	101	15542	105247	110468409
Palpitations	103.59	16.82	120	15523	159092	110414564
Deep vein thrombosis	90.26	16.82	105	15538	139782	110433874
Inappropriate schedule of product administration	89.05	16.82	126	15517	203511	110370145
Glaucoma	88.19	16.82	49	15594	22468	110551188
Cerebrovascular accident	83.48	16.82	115	15528	181169	110392487
Choroidal effusion	81.50	16.82	20	15623	870	110572786
Loss of personal independence in daily activities	74.89	16.82	99	15544	149921	110423735
Arthritis	73.70	16.82	104	15539	167482	110406174
Adverse drug reaction	71.04	16.82	81	15562	105478	110468178
Blepharitis	70.82	16.82	26	15617	4526	110569130
Choroidal detachment	63.91	16.82	16	15627	756	110572900
Confusional state	62.52	16.82	176	15467	468504	110105152
Migraine	57.68	16.82	94	15549	171558	110402098
Pulmonary embolism	55.88	16.82	105	15538	214369	110359287
Hyphaema	53.60	16.82	15	15628	1092	110572564
Product container issue	52.57	16.82	16	15627	1564	110572092
COVID-19	50.72	16.82	109	15534	244951	110328705
Somnolence	48.04	16.82	120	15523	297329	110276327
Product use in unapproved indication	44.73	16.82	152	15491	447225	110126431
Anterior chamber disorder	44.30	16.82	9	15634	162	110573494
Iridocyclitis	42.81	16.82	19	15624	5389	110568267
Depression	41.11	16.82	118	15525	317217	110256439
Intentional product use issue	41.05	16.82	101	15542	247805	110325851
Weight decreased	40.77	16.82	152	15491	467905	110105751
Trabeculectomy	39.35	16.82	7	15636	59	110573597
Ulcerative keratitis	38.55	16.82	17	15626	4749	110568907
Iritis	35.72	16.82	16	15627	4636	110569020
Vision blurred	34.62	16.82	64	15579	128958	110444698
Cataract	34.42	16.82	49	15594	79436	110494220
Visual field defect	34.27	16.82	20	15623	10052	110563604
Eye discharge	34.13	16.82	19	15624	8735	110564921
Pain in extremity	32.73	16.82	146	15497	486972	110086684
Systemic lupus erythematosus	31.41	16.82	93	15550	254245	110319411
Corneal neovascularisation	31.10	16.82	7	15636	208	110573448
Ocular hypertension	31.09	16.82	12	15631	2396	110571260
Corneal decompensation	30.95	16.82	6	15637	84	110573572
Intraocular pressure test abnormal	30.91	16.82	7	15636	214	110573442
Lacrimation increased	30.23	16.82	29	15614	30921	110542735
Floppy iris syndrome	27.63	16.82	7	15636	347	110573309
Nausea	27.34	16.82	87	15556	1235603	109338053
General physical health deterioration	27.31	16.82	13	15630	425282	110148374
Blindness	26.32	16.82	29	15614	36330	110537326
Eye complication associated with device	25.66	16.82	5	15638	72	110573584
Hypotony of eye	25.59	16.82	7	15636	468	110573188
Eye pruritus	25.23	16.82	27	15616	32748	110540908
Product substitution issue	25.20	16.82	23	15620	23038	110550618
Blindness unilateral	24.55	16.82	16	15627	9770	110563886
Conjunctival follicles	24.13	16.82	4	15639	21	110573635
Conjunctival hyperaemia	23.68	16.82	13	15630	5818	110567838
Abdominal discomfort	23.45	16.82	114	15529	393744	110179912
Maternal exposure during pregnancy	23.29	16.82	4	15639	254879	110318777
Scleral hyperaemia	23.24	16.82	6	15637	321	110573335
Arthropathy	23.23	16.82	6	15637	287516	110286140
Conjunctival scar	22.80	16.82	6	15637	346	110573310
Cardioactive drug level increased	22.52	16.82	11	15632	3871	110569785
Nasopharyngitis	21.14	16.82	15	15628	394346	110179310
Infusion related reaction	21.09	16.82	14	15629	381148	110192508
Joint swelling	21.04	16.82	19	15624	442826	110130830
Foreign body sensation in eyes	21.02	16.82	10	15633	3324	110570332
Growth of eyelashes	20.98	16.82	5	15638	192	110573464
Arthralgia	20.85	16.82	50	15593	779582	109794074
Wound	20.73	16.82	4	15639	234433	110339223
Eye inflammation	20.61	16.82	14	15629	9157	110564499
Angle closure glaucoma	20.56	16.82	10	15633	3489	110570167
Uveitis	20.56	16.82	20	15623	21690	110551966
Product quality issue	20.29	16.82	38	15605	77261	110496395
No adverse event	20.27	16.82	37	15606	73802	110499854
Product delivery mechanism issue	19.77	16.82	5	15638	246	110573410
Gastrointestinal disorder	19.63	16.82	5	15638	241947	110331709
Cystoid macular oedema	19.51	16.82	9	15634	2791	110570865
Erythema of eyelid	19.49	16.82	10	15633	3905	110569751
Retinal vascular occlusion	19.37	16.82	6	15637	622	110573034
Visual impairment	19.36	16.82	52	15591	134376	110439280
Drug ineffective	19.07	16.82	311	15332	1520229	109053427
Macular oedema	18.99	16.82	12	15631	6954	110566702
Corneal opacity	18.92	16.82	7	15636	1244	110572412
Hepatic enzyme increased	18.84	16.82	11	15632	320881	110252775
Pericarditis	18.83	16.82	4	15639	219110	110354546
Glaucoma surgery	18.21	16.82	4	15639	106	110573550
Vitreous haemorrhage	17.94	16.82	10	15633	4610	110569046
Conjunctivitis	17.93	16.82	23	15620	33769	110539887
Tracheobronchitis bacterial	17.90	16.82	3	15640	17	110573639
Infection	17.85	16.82	15	15628	362185	110211471
Conjunctival oedema	17.44	16.82	7	15636	1549	110572107
Bradycardia	17.43	16.82	55	15588	155462	110418194
Urticaria	17.25	16.82	12	15631	318845	110254811
Glossodynia	17.24	16.82	5	15638	221999	110351657
Eczema eyelids	17.14	16.82	5	15638	422	110573234
Febrile neutropenia	17.03	16.82	12	15631	316755	110256901
Abdominal pain	17.03	16.82	29	15614	512960	110060696
Hyperaemia	16.96	16.82	9	15634	3764	110569892
Corneal perforation	16.89	16.82	6	15637	950	110572706

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01EC03	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Carbonic anhydrase inhibitors
ATC	S01EE52	SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Prostaglandin analogues
FDA MoA	N0000000235	Carbonic Anhydrase Inhibitors
FDA EPC	N0000175517	Carbonic Anhydrase Inhibitor
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002257	Carbonic Anhydrase Inhibitors
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
CHEBI has role	CHEBI:23018	EC 4.2.1.1 (carbonic anhydrase) inhibitor
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:39456	antiglaucoma drug
CHEBI has role	CHEBI:66981	ophthalmology drug

Related Drugs by ATC class:

S01EC Carbonic anhydrase inhibitors 4 drugs

acetazolamidebrinzolamidedichlorphenamidemethazolamide

S01EE Prostaglandin analogues 6 drugs

bimatoprostlatanoprostlatanoprostene bunodnetarsudiltafluprosttravoprost

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ocular hypertension	indication	4210003	DOID:9282
Open-angle glaucoma	indication	84494001	DOID:1067
Bronchospasm	contraindication	4386001
Complete atrioventricular block	contraindication	27885002
Acute cerebrovascular insufficiency	contraindication	29322000
Hyperthyroidism	contraindication	34486009	DOID:7998
Anaphylaxis	contraindication	39579001
Sinus bradycardia	contraindication	49710005
General anesthesia	contraindication	50697003
Acute nephropathy	contraindication	58574008
Diabetes mellitus	contraindication	73211009	DOID:9351
Pulmonary emphysema	contraindication	87433001
Cardiogenic shock	contraindication	89138009
Myasthenia gravis	contraindication	91637004	DOID:437
Partial atrioventricular block	contraindication	195039008
Decompensated cardiac failure	contraindication	195111005
Hypoglycemic disorder	contraindication	237630007
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.73	acidic
pKa2	8.34	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN	INHIBITOR	Ki	9.70		CHEMBL	CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		IC50	7.19		CHEMBL
Carbonic anhydrase 1	Enzyme	P00915	CAH1_HUMAN		Ki	6.30		CHEMBL
Carbonic anhydrase 4	Enzyme	P22748	CAH4_HUMAN		Ki	7.37		CHEMBL
Carbonic anhydrase 9	Enzyme	Q16790	CAH9_HUMAN		Ki	7.28		CHEMBL
Carbonic anhydrase 12	Enzyme	O43570	CAH12_HUMAN		Ki	8.46		CHEMBL
Carbonic anhydrase 5A, mitochondrial	Enzyme	P35218	CAH5A_HUMAN		Ki	7.38		CHEMBL
Carbonic anhydrase 5B, mitochondrial	Enzyme	Q9Y2D0	CAH5B_HUMAN		Ki	7.48		CHEMBL
Carbonic anhydrase 7	Enzyme	P43166	CAH7_HUMAN		Ki	8.46		CHEMBL
Carbonic anhydrase 3	Enzyme	P07451	CAH3_HUMAN		Ki	5.10		CHEMBL
Carbonic anhydrase 14	Enzyme	Q9ULX7	CAH14_HUMAN		Ki	7.57		CHEMBL
Carbonic anhydrase 13	Enzyme	Q8N1Q1	CAH13_HUMAN		Ki	7.74		CHEMBL
Carbonic anhydrase 6	Enzyme	P23280	CAH6_HUMAN		Ki	8		CHEMBL
Carbonic anhydrase	Enzyme		CYNT_HELPY		Ki	5.37		CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	7.96		CHEMBL
Carbonic anhydrase 13	Enzyme		CAH13_MOUSE		Ki	7.74		CHEMBL
Carbonic anhydrase 4	Enzyme		CAH4_BOVIN		Ki	7.37		CHEMBL
Carbonic anhydrase	Enzyme		CAH_METTE		Ki	6.39		CHEMBL
Carbonic anhydrase	Enzyme		Q50565_METTH		Ki	4.51		CHEMBL
Carbonic anhydrase 15	Enzyme		CAH15_MOUSE		Ki	7.21		CHEMBL
Carbonic anhydrase	Enzyme		CAN_YEAST		Ki	6.96		CHEMBL
Carbonic anhydrase	Enzyme		CAN_CANAL		Ki	8.05		CHEMBL
Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase	Enzyme		P96878_MYCTU		Ki	6.86		CHEMBL
Carbonic anhydrase	Enzyme		Q6FTL6_CANGA		Ki	5.18		CHEMBL
Alpha carbonic anhydrase	Enzyme		B5SU02_9CNID		Ki	7.74		CHEMBL
Carbonic anhydrase	Enzyme		C0IX24_9CNID		Ki	6.95		CHEMBL
Carbonic anhydrase 2	Enzyme		Q3I4V7_CRYNV		Ki	5.08		CHEMBL
Astrosclerin-3	Enzyme		A6YCJ1_9METZ		Ki	6.55		CHEMBL
Beta-carbonic anhydrase 1	Enzyme		MTCA1_MYCTU		Ki	6.13		CHEMBL
Delta carbonic anhydrase	Enzyme		Q5U9J1_THAWE		Ki	7.30		CHEMBL
Carbonic anhydrase 2	Enzyme		MTCA2_MYCTU		Ki	7		CHEMBL
Carbonic anhydrase	Enzyme		Q5TU56_ANOGA		Ki	6.56		CHEMBL
Carbonic anhydrase, alpha family	Enzyme		Q31FD6_HYDCU		Ki	8.15		CHEMBL
Carbonate dehydratase	Enzyme		B2V8E3_SULSY		Ki	8.10		CHEMBL

External reference:

ID	Source
4023982	VUID
N0000021987	NUI
D00653	KEGG_DRUG
130693-82-2	SECONDARY_CAS_RN
4020910	VANDF
4023982	VANDF
C0165590	UMLSCUI
CHEBI:4702	CHEBI
ETS	PDB_CHEM_ID
CHEMBL218490	ChEMBL_ID
CHEMBL1201162	ChEMBL_ID
DB00869	DRUGBANK_ID
C062765	MESH_SUPPLEMENTAL_RECORD_UI
5284549	PUBCHEM_CID
6810	IUPHAR_LIGAND_ID
6960	INN_ID
9JDX055TW1	UNII
236065	RXNORM
158838	MMSL
29194	MMSL
4634	MMSL
004998	NDDF
004999	NDDF
108834004	SNOMEDCT_US
126154004	SNOMEDCT_US
373447009	SNOMEDCT_US
9JDX055TW1	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dorzolamide Hydrochloride	Human Prescription Drug Label	1	14445-404	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
DORZOLAMIDE HYDROCHLORIDE TIMOLOL MALETAE	Human Prescription Drug Label	2	14445-405	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
COSOPT PF	HUMAN PRESCRIPTION DRUG LABEL	2	17478-604	SOLUTION/ DROPS	20 mg	OPHTHALMIC	NDA	26 sections
COSOPT	HUMAN PRESCRIPTION DRUG LABEL	2	17478-605	SOLUTION/ DROPS	20 mg	OPHTHALMIC	NDA	28 sections
Dorzolamide HCl	HUMAN PRESCRIPTION DRUG LABEL	1	24208-485	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	25 sections
Dorzolamide Hydrochloride and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	24208-486	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	25 sections
Dorzolamide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	25021-006	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	28 sections
Dorzolamide Hydrochloride Ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	1	42571-141	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride and Timolol Maleate ophthalmic Solution	HUMAN PRESCRIPTION DRUG LABEL	2	42571-147	SOLUTION/ DROPS	22.30 mg	OPHTHALMIC	ANDA	24 sections
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE	HUMAN PRESCRIPTION DRUG LABEL	2	42571-382	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	25 sections
Dorzolamide Hydrochloride	Human Prescription Drug Label	1	46708-519	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution	Human Prescription Drug Label	2	46708-553	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-1246	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide HCl	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2406	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	25 sections
Dorzolamide HCl	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2768	SOLUTION	20 mg	OPHTHALMIC	ANDA	25 sections
Dorzolamide HCl and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	50090-2867	SOLUTION	20 mg	OPHTHALMIC	ANDA	26 sections
Dorzolamide Hydrochloride Ophthalmic	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4882	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	50090-6371	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	25 sections
Dorzolamide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50383-232	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	50383-233	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	50383-261	SOLUTION/ DROPS	20 mg	OPHTHALMIC	NDA	24 sections
Dorzolamide hydrochloride and timolol maleate	HUMAN PRESCRIPTION DRUG LABEL	2	50742-323	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections
Cosopt	HUMAN PRESCRIPTION DRUG LABEL	2	54868-4279	SOLUTION	20 mg	OPHTHALMIC	NDA	26 sections
Dorzolamide Hydrochloride and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5982	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	23 sections
Dorzolamide HCl	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6330	SOLUTION/ DROPS	22.30 mg	OPHTHALMIC	ANDA	22 sections
Dorzolamide and Timolol	HUMAN PRESCRIPTION DRUG LABEL	2	55545-1007	SOLUTION	20 mg	OPHTHALMIC	ANDA	1 sections
Dorzolamide hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	55545-1008	SOLUTION	20 mg	OPHTHALMIC	ANDA	1 sections
DORZOLAMIDE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	61314-019	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	26 sections
Dorzolamide Hydrochloride and Timolol Maleate	HUMAN PRESCRIPTION DRUG LABEL	2	61314-030	SOLUTION	20 mg	OPHTHALMIC	ANDA	24 sections
Dorzolamide Hydrochloride	Human Prescription Drug Label	1	62332-519	SOLUTION/ DROPS	20 mg	OPHTHALMIC	ANDA	24 sections